InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.120 0.005 (4.35%)+
Announcement
Release
10 Jun 2026 8:19AM
Price at Release
$0.115
Full Release
download
Summary
Argenica Therapeutics Limited, an Australian biotechnology company, announced that the World Health Organisation has confirmed 'xaranetide' as the International Nonproprietary Name (INN) for its neuroprotective drug candidate, ARG-007. This development represents a key milestone in the advancement of ARG-007, facilitating its recognition and communication within regulatory, scientific, and medical communities globally as xaranetide. The confirmation follows a formal WHO review process without any objections, paving the way for further clinical development and partnerships.
Key Points
  • Argenica Therapeutics Limited is developing ARG-007, a neuroprotective drug candidate.
  • The World Health Organisation confirmed xaranetide as the International Nonproprietary Name (INN) for ARG-007.
  • The confirmation of xaranetide as INN marks a significant milestone for the company.
  • Xaranetide will be used as the generic name for ARG-007 in global communications.
  • No objections were expressed during the WHO consultation process for the INN.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.